Fight Retinal Blindness SPAIN. Report 3: clinical outcomes of vascular endothelial growth factor inhibitors in low vision eyes with neovascular age-related macular degeneration. A national database study

Indexed in

License and use

Citations

Altmetrics

Grant support

This work was supported in part by a grant from Novartis Pharmaceuticals. No member or affiliate of Novartis had any input into data analysis, interpretation of the data, or writing the manuscript.

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Figueras Ventura, Rosa MariaAuthorMartín-Pinardel, RubenAuthorParrado-Carrillo, AlbaAuthorMoll-Udina, AinaAuthorBernal-Morales, CarolinaAuthorFigueras-Roca, MarcAuthorCasaroli-Marano, Ricardo PAuthorZarranz-Ventura, JavierAuthor

January 21, 2025

Publications

Article

Publicated to:Eye. 38 (18): 3450-3458 - 2024-09-21 38(18), DOI: 10.1038/s41433-024-03322-8

Authors: Puzo, Martin; Calvo-Perez, Pilar; Bartol-Puyal, Francisco; Sanchez-Monroy, Jorge; Martin-Pinardel, Ruben; Parrado-Carrillo, Alba; Moll-Udina, Aina; Bernal-Morales, Carolina; Sanchez-Vela, Laura; Sararols-Ramsay, Laura; Garay-Aramburu, Gonzaga; Arruabarrena, Carolina; Garcia-Arumi, Jose; Abraldes, Maximino; Ruiz-Moreno, Jose Maria; Valldeperas, Xavier; Velazquez-Villoria, Daniel; Escobar-Barranco, Jose Juan; Gallego-Pinazo, Roberto; Figueroa, Marta S; Figueras-Roca, Marc; Barthelmes, Daniel; Gillies, Mark C; Casaroli-Marano, Ricardo P; Zarranz-Ventura, Javier

Affiliations

Clin Villoria, Pontevedra, Spain - Author

Fundacio Privada Hosp Asil Granollers, Granollers, Spain - Author

Fundacio Recerca Clin Barcelona, Inst Invest Biomed August Pi & Sunyer FRCB IDIBAPS, Barcelona, Spain - Author

Hosp Badalona Germans Trias & Pujol, Badalona, Spain - Author

Hosp Conxo, Santiago De Compostela, Spain - Author

Hosp Maig, Barcelona, Spain - Author

Hosp Univ Principe Asturias, Madrid, Spain - Author

Hosp Univ Puerta Hierro, Madrid, Spain - Author

Hosp Univ Ramon & Cajal, Madrid, Spain - Author

Hosp Univ Vall Hebron, Barcelona, Spain - Author

Oftalvist Valencia, Valencia, Spain - Author

OSI Araba, Vitoria, Spain - Author

Univ Barcelona, Hosp Clin Barcelona, Barcelona, Spain - Author

Univ Barcelona, Sch Med, Dept Surg, Barcelona, Spain - Author

Univ Sydney, Save Sight Inst, Sydney Med Sch, Sydney, NSW, Australia - Author

Univ Zaragoza, Miguel Servet Univ Hosp, Miguel Servet Ophthalmol Innovat & Res Grp GIMSO, Zaragoza, Spain - Author

Univ Zurich, Univ Hosp Zurich, Zurich, Switzerland - Author

Abstract

ObjectivesTo compare visual outcomes for low vision eyes (LVE) (20/200 Snellen) at the time of the first injection in a clinical practice setting. MethodsSubgroup analysis of a multicenter national database of treatment- na & iuml;ve eyes neovascular age related macular degeneration (nAMD) treated with anti-VEGF intravitreal injections divided into LVE and NLVE. Demographics, visual acuity (VA) at baseline and subsequent timepoints (12, 24, and 36 months), number of injections and visits data were collected using a validated web-based tool (Fight Retinal Blindness!). Results3138 eyes were included, 705 LVE and 2433 NLVE. The LVE group had the greatest VA gain (p < 0.001), at 12, 24, and 36 months (+15, +15, and +13 letters respectively). The proportion of patients with VA loss (-5 letters) differed between groups at 12, 24, and 36 and was significantly greater (p < 0.001) in NLVE. The proportion of patients with VA gain (+5 letters) was significantly higher (p < 0.001) in LVE in all timeframes. The proportions of LVE that still had VA = 70 letters at 12, 24, and 36 months. LVE received fewer intravitreal injections than NLVE throughout follow-up (6, 9, 12 vs 7, 11, 15). ConclusionFindings of this study support the need for ongoing therapy in patients with initial visual acuity less than 35 letters since sustained visual improvements can be achieved and maintained for the first 3 years of treatment.

Keywords

2.0 mg ranibizumabAgedAged, 80 and overAngiogenesis inhibitorsBevacizumabDatabases, factualEfficacyFemaleGood health and well-beingHumansIntravitreal injectionsMaleManagementPopulationRanibizumabReceptors, vascular endothelial growth factorRetrospective studiesSafetSpainTreatment outcomeVascular endothelial growth factor aVegfa protein, humanVision, lowVisual acuityVisual impairmentWet macular degeneration

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal EYE due to its progression and the good impact it has achieved in recent years, according to the agency Scopus (SJR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position , thus managing to position itself as a Q1 (Primer Cuartil), in the category Arts and Humanities (Miscellaneous). Notably, the journal is positioned above the 90th percentile.

Impact and social visibility

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Australia; Switzerland.

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Zarranz Ventura, Javier).